Nazneen Noorani, MD
Family Medicine · Riverview, FLNPI 1942386750
Payments from drug & device makers
Across 120 payments — averaging $20.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$398
- AstraZeneca$297
- Novo Nordisk$268
- Abbott$221
- AbbVie$160
- Painteq LLC$140
- plus $961 from 20 others
What the payments were for
- Food & beverage$2,444100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 24 | $398 |
| AstraZeneca | 18 | $297 |
| Novo Nordisk | 14 | $268 |
| Abbott | 5 | $221 |
| AbbVie | 8 | $160 |
| Painteq LLC | 1 | $140 |
| Pfizer | 5 | $104 |
| Boehringer Ingelheim | 6 | $103 |
| Amarin Pharma, Inc. | 5 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $83 |
| GSK | 4 | $76 |
| Johnson & Johnson | 3 | $55 |
| Exact Sciences | 3 | $52 |
| Bayer | 2 | $49 |
| Amgen(2 entities) | 3 | $48 |
| Inspire Medical Systems, Inc. | 1 | $43 |
| Hologic Sales And Service, LLC | 2 | $42 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| IBSA Pharma Inc. | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Medtronic | 1 | $24 |
| Arbor Pharmaceuticals, Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Optinose US, Inc. | 1 | $18 |
| Kaleo, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Confirm Rx$142
- PAINTEQ$140
How this compares
$2,444 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 85 | $124,850 |
| FarxigaDapagliflozin Propanediol | 82 | $106,099 |
| TrulicityDulaglutide | 30 | $51,866 |
| OzempicSemaglutide | 36 | $48,736 |
| MounjaroTirzepatide | 32 | $48,086 |
| JardianceEmpagliflozin | 49 | $46,431 |
| JanuviaSitagliptin Phosphate | 36 | $42,050 |
| XareltoRivaroxaban | 20 | $31,641 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 36 | $14,809 |
| Spiriva RespimatTiotropium Bromide | 11 | $11,880 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 71 | $11,708 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 52 | $11,642 |
| MyrbetriqMirabegron | 16 | $10,718 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $10,596 |
| Rezvoglar KwikpenInsulin Glargine-Aglr | 45 | $9,490 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $104 | $124,85085 claims |
| AstraZenecaFarxiga, Symbicort | $297 | $112,256101 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $398 | $99,95262 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $103 | $58,31060 claims |
| Novo NordiskOzempic | $268 | $48,73636 claims |
| Johnson & JohnsonXarelto | $55 | $31,64120 claims |
| AbbVieSynthroid | $160 | $3,02752 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Riverview
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.